EUCTR2012-000075-16-NO进行中（未招募）1 期
Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,925
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Has provided written informed consent. Subjects must be able to understand and be willing to sign the written informed consent form (ICF). A signed ICF must be appropriately obtained prior to the conduct of the any trial- specific procedure.
- •Age = 18 years
- •Histologically or cytologically confirmed prostate cancer
- •Patients diagnosed with progressive bone predominant metastatic CRPC/HRPC with at least two skeletal metastases on bone scan with no lung, liver, and/or brain metastasis (lymph node only metastasis is allowed)
- •Progressive disease is defined either by:
- •oThe appearance of new bone lesions. If progression is based on new lesion(s) on bone scan only without an increase in PSA, PSA values from 3 assessments within the last 6 months must be provided; OR
- •oIn the absence of a new bone lesions by 2 consecutive increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA =5 ng/mL
- •Life expectancy = 6 months
- •ECOG PS 0-2
- •Adequate hematological, liver and renal function
- •oAbsolute neutrophil count (ANC) = 1.5 x109/L
- •oPlatelet count = 100 x109/L
- •oHemoglobin =10.0 g/dL (100 g/L; 6.2 mmol/L)
- •oTotal bilirubin level = 1.5 x institutional upper limit of normal (ULN)
- •oAspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN
- •oCreatinine = 1.5 x ULN
- •oAlbumin > 25 g/L
- •Willing and able to comply with the protocol, including follow-up visits and examinations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 925
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1000
排除标准
- •Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period or follow-up
- •Eligible for first course of docetaxel, i.e., patients who are fit enough, willing, and who are located where treatment with docetaxel is available
- •Treatment with cytotoxic chemotherapy within previous 4 weeks, or failure to recover from AEs due to cytotoxic chemotherapy administered more than 4 weeks previous (however, ongoing neuropathy is permitted)
- •Received previous radiotherapy to approximately > 25% of bone marrow, including hemibody radiation
- •Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 chloride) for the treatment of bony metastases
- •Other malignancy treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)
- •Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality
- •Presence of brain metastases
- •Lymphadenopathy exceeding 6 cm in short-axis diameter
- •Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis.
- •Imminent or history of spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI)
- •Any other serious illness or medical condition, such as but not limited to:
- •oAny infection = NCI-CTCAE v.4.03 Grade 2
- •oCardiac failure New York Heart Association (NYHA) III or IV
- •oCrohn’s disease or ulcerative colitis
- •oBone marrow dysplasia
- •Fecal incontinence
研究者
相似试验
进行中（未招募）
不适用
Radium-223 Chloride in the treatment patients diagnosed with prostate cancer that has spread to the boneCastrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasisMedDRA version: 14.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000075-16-ITBAYER HEALTHCARE AG1,925
进行中（未招募）
1 期
Radium-223 Chloride in the treatment patients diagnosed with prostate cancer that has spread to the boneEUCTR2012-000075-16-ESBayer HealthCare AG1,925
进行中（未招募）
1 期
Radium-223 Dichloride in the treatment of patients diagnosed with prostate cancer that has spread to the boneCastrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasisMedDRA version: 19.0Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2012-000075-16-DEBayer AG1,350
已完成
3 期
Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone MetastasisCastrate-resistant prostate cancer1003859710036958Prostate cancerNL-OMON39188Bayer18
进行中（未招募）
1 期
Radium-223 Dichloride in the treatment of patients diagnosed with prostate cancer that has spread to the boneCastrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasisMedDRA version: 16.0Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2012-000075-16-CZBayer HealthCare AG1,500